{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT04673396: Phase 1 Interventional Unknown status Solid Tumor
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Endothal (also known as Endothall), a herbicide for terrestrial and aquatic plants, is a potent, selective protein phosphatase 2A (PP2A) inhibitor. It also inhibits protein phosphatase 1 (PP1). Endothall is considered safe in drinking water, but in case of consumption for a long period, it can cause stomach or intestinal problems.
Status:
Investigational
Source:
NCT04698603: Phase 1/Phase 2 Interventional Completed Treatment Resistant Depression
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
N,N-Dimethyl-5-Methoxytryptamine (aka 5-MeO-DMT) is a psychedelic of the tryptamine class. It is found in a wide variety of plant species, and a single psychoactive toad species, the Colorado River toad. Like its close relatives DMT and bufotenin (5-HO-DMT), it has been used as an entheogen in South America. It can also be found in the dart poison traditionally used by the Yanoama Indians of Upper Orinoco. It acts as a non-selective serotonin (5-HT) agonist. -MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine. 5-MeO-DMT is classified as a controlled substance in China, Australia, Sweden, Turkey, and the USA.
Status:
Investigational
Source:
NCT01527838: Phase 1 Interventional Completed Non-Hodgkin's Lymphoma (NHL)
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
16,16-dimethyl Prostaglandin E2 acts as an agonist on most prostaglandin E (EP) receptor subtypes, it has prolonged half-life in vivo, because it is not a substrate for the enzyme 15-hydroxy prostaglandin dehydrogenase. This compound was studied by Fate Therapeutics in phase I clinical trials under the name FT1050 or ProHema-CB for pediatric patients with hematologic malignancies. However, this study was terminated.
Class (Stereo):
CHEMICAL (ACHIRAL)
Furobufen, a propionic acid derivative produced anti-inflammatory, antiarthritic, and antipyretic effects. It was shown that this compound could reduce the pain resulting from an acute inflammatory reaction and the activity profile of furobufen was similar to that of the non-steroidal anti-inflammatory drugs. Information about the current development of this compound is not available.
Status:
Investigational
Source:
NCT04439188: Phase 2 Interventional Active, not recruiting Advanced Lymphoma
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
GSK-2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. GSK-2636771 shows selectively inhibitory activity in PTEN null cell lines (human prostate adenocarcinoma PC-3 and breast cancer HCC70) with EC50 of 36 nM and 72 nM, respectively. GSK-2636771 significantly decreases cell viability in p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines, and leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines. On April 1 2016 GlaxoSmithKine completes a phase-I/II trial for Solid tumours (Late-stage disease) in USA, United Kingdom and South Korea (NCT01458067).
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Diaziquone is an aziridinylbenzoquinone with properties suggestive of an alkylating agent. The drug has shown broad antitumor activity against numerous transplantable murine tumors including curative activity against several intracerebrally implanted tumors. Diaziquone is rapidly and extensively metabolized by the liver. Diaziquone is a potent marrow suppressive agent inducing significant degrees of leukopenia, granulocytopenia, and thrombocytopenia in humans. Thrombocytopenia is often severe. Diaziquone alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. This agent can also form free radicals, thereby initiating DNA damage via DNA strand breaks. Due to its lipophilicity, diaziquone readily crosses the blood brain barrier. In phase I and preliminary phase II trials, diaziquone has demonstrated activity against primary brain tumors. Little activity has been seen in other tumor categories.
Status:
Investigational
Source:
NCT00979173: Phase 1 Interventional Completed Glioma
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
BMS 599626 is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM. BMS-599626 is identified as an ATP-competitive inhibitor for HER1 and as an ATP-noncompetitive inhibitor for HER2. BMS-599626 inhibits the proliferation of tumor cells expressing high levels of HER1 and/or HER2, including Sal2, BT474, N87, KPL-4, HCC202, HCC1954, HCC1419, AU565, ZR-75-30, MDA-MB-175, GEO, and PC9 cells. In a phase I trial of solid tumour patients receiving BMS 599626 no doselimiting toxicities were observed during the first cycle. Grade 1 or 2 drugrelated effects were reported and included diarrhoea, nausea, vomiting, rash, fatigue, musculoskeletal pain/cramp and cough. BristolMyers Squibb discontinued development of BMS 599626 for cancer in July 2015
Status:
Investigational
Source:
USAN:LODOXAMIDE ETHYL [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Lodoxamide ethyl, diethyl N,N'-(2-chloro-5-cyano-m-phenylene) dioxamate, is an orally active candidate for the treatment of asthma and other allergic diseases. Lodoxamide ethyl prevents mast cell mediator release during allergic reactions in rats, guinea pigs, and monkeys at doses well below toxic levels. Lodoxamide ethyl does not interfere with antigen-antibody interaction, does not antagonize the effects of histamine or slow-reacting substance of anaphylaxis, and does not have direct antiinflammatory effects. Lodoxamide ethyl has been proven capable of preventing bronchospasm in humans when the subject was given 1, 3, or 10 mg of the drug orally prior to challenge with an antigen.
Status:
Investigational
Source:
NCT00921128: Phase 1 Interventional Withdrawn Parkinson's Disease
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Muscimol is one of the principal psychoactive constituents of Amanita muscaria and related species of mushroom. Muscimol is a potent, selective agonist for the GABAAreceptors and displays sedative-hypnotic, depressant and hallucinogenic psychoactivity. The effects of the Amanita mushrooms begin 30–120 minutes after consumption and the effects last for 5–10 hours. Some of the desired effects include euphoria, dream-like (lucid) state of mind, out-of-body experiences, and synesthesia. Neutral effects include dizziness, clumsiness, the feeling of increased physical strength, loss of equilibrium, and a glassy-eyed stare. Calming effects may be felt, but completely opposite effects such as extreme energy bursts have been described. Negative effects include mild to moderate nausea, stomach discomfort, increased salivation, and muscle twitching or tremors. In large doses, strong dissociation or delirium may be felt.
Status:
Investigational
Source:
NCT03106688: Not Applicable Interventional Unknown status Obesity
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
